Comparing Shattuck Labs (NASDAQ:STTK) & Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Dianthus Therapeutics and Shattuck Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	0	0	7	2	3.22
Shattuck Labs	0	4	1	2	2.71

Dianthus Therapeutics presently has a consensus target price of $54.33, indicating a potential upside of 208.54%. Shattuck Labs has a consensus target price of $7.50, indicating a potential upside of 689.56%. Given Shattuck Labs’ higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Dianthus Therapeutics.

Risk and Volatility

Dianthus Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Earnings & Valuation

This table compares Dianthus Therapeutics and Shattuck Labs”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$6.24 million	90.73	-$43.56 million	($2.60)	-6.77
Shattuck Labs	$5.72 million	7.95	-$87.30 million	($1.49)	-0.64

Dianthus Therapeutics has higher revenue and earnings than Shattuck Labs. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dianthus Therapeutics and Shattuck Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-1,250.32%	-21.68%	-20.88%
Shattuck Labs	-1,156.46%	-61.92%	-54.49%

Institutional and Insider Ownership

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 10.5% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Dianthus Therapeutics beats Shattuck Labs on 8 of the 14 factors compared between the two stocks.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.